Viridian Therapeutics, Inc. (0K1R.L)
USD 13.33
(-8.32%)
USD 13.33
(-8.32%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 490.42 Million USD | 12.72% |
| 2022 | 435.09 Million USD | 113.58% |
| 2021 | 203.7 Million USD | 55.2% |
| 2020 | 131.25 Million USD | 333.73% |
| 2019 | 30.26 Million USD | -54.25% |
| 2018 | 66.14 Million USD | 26.04% |
| 2017 | 52.48 Million USD | 1132.24% |
| 2016 | 4.25 Million USD | -66.99% |
| 2015 | 12.9 Million USD | 59.5% |
| 2014 | 8.08 Million USD | 120.25% |
| 2013 | 3.67 Million USD | 32.08% |
| 2012 | 2.78 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 630.38 Million USD | 28.54% |
| 2024 Q2 | 585.66 Million USD | -7.09% |
| 2023 Q2 | 351.46 Million USD | -9.1% |
| 2023 Q3 | 328.75 Million USD | -6.46% |
| 2023 Q4 | 490.42 Million USD | 49.18% |
| 2023 FY | 490.42 Million USD | 12.72% |
| 2023 Q1 | 386.64 Million USD | -11.14% |
| 2022 Q1 | 183.16 Million USD | -10.08% |
| 2022 Q3 | 440.58 Million USD | 159.45% |
| 2022 Q2 | 169.81 Million USD | -7.29% |
| 2022 Q4 | 435.09 Million USD | -1.25% |
| 2022 FY | 435.09 Million USD | 113.58% |
| 2021 Q1 | 122.83 Million USD | -6.42% |
| 2021 Q3 | 221.2 Million USD | 87.14% |
| 2021 Q4 | 203.7 Million USD | -7.91% |
| 2021 FY | 203.7 Million USD | 55.2% |
| 2021 Q2 | 118.2 Million USD | -3.77% |
| 2020 Q1 | 39.05 Million USD | 29.04% |
| 2020 Q2 | 33.48 Million USD | -14.25% |
| 2020 FY | 131.25 Million USD | 333.73% |
| 2020 Q4 | 131.25 Million USD | 299.77% |
| 2020 Q3 | 32.83 Million USD | -1.95% |
| 2019 Q2 | 48.78 Million USD | -11.22% |
| 2019 FY | 30.26 Million USD | -54.25% |
| 2019 Q4 | 30.26 Million USD | -22.03% |
| 2019 Q3 | 38.81 Million USD | -20.44% |
| 2019 Q1 | 54.95 Million USD | -16.93% |
| 2018 FY | 66.14 Million USD | 26.04% |
| 2018 Q1 | 86.99 Million USD | 65.76% |
| 2018 Q3 | 76.55 Million USD | -6.51% |
| 2018 Q4 | 66.14 Million USD | -13.59% |
| 2018 Q2 | 81.88 Million USD | -5.87% |
| 2017 Q1 | 57.79 Million USD | 1256.99% |
| 2017 FY | 52.48 Million USD | 1132.24% |
| 2017 Q4 | 52.48 Million USD | 11.47% |
| 2017 Q3 | 47.08 Million USD | -5.89% |
| 2017 Q2 | 50.02 Million USD | -13.44% |
| 2016 Q3 | 7.54 Million USD | -16.6% |
| 2016 Q4 | 4.25 Million USD | -43.52% |
| 2016 Q2 | 9.04 Million USD | -16.25% |
| 2016 Q1 | 10.79 Million USD | -16.32% |
| 2016 FY | 4.25 Million USD | -66.99% |
| 2015 Q4 | 12.9 Million USD | -12.81% |
| 2015 Q1 | 15.74 Million USD | 94.67% |
| 2015 FY | 12.9 Million USD | 59.5% |
| 2015 Q3 | 14.79 Million USD | 13.01% |
| 2015 Q2 | 13.09 Million USD | -16.85% |
| 2014 Q4 | 8.08 Million USD | -15.07% |
| 2014 Q1 | 3.49 Million USD | -4.83% |
| 2014 Q2 | 10.66 Million USD | 205.06% |
| 2014 Q3 | 9.52 Million USD | -10.67% |
| 2014 FY | 8.08 Million USD | 120.25% |
| 2013 Q4 | 3.67 Million USD | 0.0% |
| 2013 FY | 3.67 Million USD | 32.08% |
| 2012 FY | 2.78 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -43.905% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 35.939% |
| Codexis, Inc. | 136.56 Million USD | -259.124% |
| Organovo Holdings, Inc. | 6.34 Million USD | -7624.429% |